A study of novel anti-cancer agents in patients with metastatic triple negative breast cancer

Trial Identifier: D933LC00001
Sponsor: AstraZeneca
Start Date: December 2018
Primary Completion Date: November 2024
Study Completion Date: February 2027
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, BC Kelowna, BC, CA, V1Y 5L3
CA, ON London, ON, CA, N6A 5W9
CA, QC Greenfield Park, QC, CA, J4V 2H1
CA, QC Montreal, QC, CA, H4A 3J1
GB Cambridge, GB, CB2 0QQ
GB London, GB, EC1M 6BQ
GB Manchester, GB, M20 4BX
GB Oxford, GB, OX3 7LE
KR seoul, KR, 06351
KR Seoul, KR, 05505
KR Seoul, KR, 03080
PL Gdańsk, PL, 80-952
PL Kraków, PL, 31-501
PL Lublin, PL, 20-090
PL Opole, PL, 45-060
PL Rzeszów, PL, 35-021
PL Warszawa, PL, 02-781
PL Warszawa, PL, 04-141
TW Kaohsiung, TW, 80756
TW Taichung, TW, 40447
TW Tainan City, TW, 70403
TW Taipei, TW, 10002
TW Taipei, TW, 112
TW Taoyuan, TW, 333
US, AZ Tucson, AZ, US, 85715
US, MA Boston, MA, US, 02215
US, MA Boston, MA, US, 02114
US, MD Columbia, MD, US, 21044
US, MI Grand Rapids, MI, US, 49503
US, MO Saint Louis, MO, US, 63110
US, TX Dallas, TX, US, 75246
US, VA Williamsburg, VA, US, 23188